Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nestle sales

This article was originally published in The Tan Sheet

Executive Summary

"Robust innovation and renovation pipeline" for infant formula contributed to 6.6% growth in Nestle Nutrition sales to 5.7 bil. Swiss Francs ($4.87 bil.) for the January-September period, company announces Oct. 18. For the nine-month period, organic sales advanced 9.7%, "in line with the business' long-term target of 10%," firm adds. "NAN premium starter formulas and Nestle infant cereals enriched with probiotics to strengthen infants' immune systems, did particularly well in their global rollout," according to Nestle. Firm's Powdered and Liquid Beverages unit achieved sales of 12.8 bil. Swiss Francs ($10.9 bil.), representing growth of 7.5%, or 10% organically. Nestle also announces promotion of Acquisitions and Business Development Chief Jim Singh to CFO, and Paul Polman as head of Zone Americas, replacing Paul Bulcke, who will assume the CEO post in the spring (1"The Tan Sheet" Oct. 1, 2007, In Brief)...

You may also be interested in...

Nestle proposes new CEO

Nestle's board of directors proposes Paul Bulcke, a member of Nestle's executive board and head of Zone Americas, take on the role of CEO at the firm's next annual board meeting April 10, 2008. Current CEO Peter Brabeck-Letmathe will serve as active, non-executive, chairman, Nestle said Sept. 20. The board cites the decision to separate the chairman and CEO positions, anticipating an increasing workload for the chairman's office, and the desire for management continuity by entrusting the CEO position to a younger person as reasons for appointing Bulcke. Bulcke's nomination took place under the leadership of the independent Compensation and Nomination Committee and was received unanimous approval by the board. Bulcke's successor at Zone Americas will be announced Oct. 18...

QUOTED. 29 September 2020. Phil Brown.

ABHI’s Phil Brown believes the future of UK device regulation will be innovation-friendly and patient-responsive system – but doesn’t expect easy alignment with the EU. See what he had to say.

COVID-19 Vaccines: HHS Advisory Committee Urges ‘Great Caution’ On Use Of EUA

Biologics license application is preferred route to market, but if emergency authorization is given it should happen with full transparency and be communicated in a clear manner to strengthen public confidence, National Vaccine Advisory Committee says.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts